{"id":"NCT04545060","sponsor":"Vir Biotechnology, Inc.","briefTitle":"VIR-7831 for the Early Treatment of COVID-19 in Outpatients","officialTitle":"A Phase II/III Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-08-27","primaryCompletion":"2021-04-08","completion":"2021-09-02","firstPosted":"2020-09-10","resultsPosted":"2022-11-07","lastUpdate":"2022-11-07"},"enrollment":1057,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Covid19"],"interventions":[{"type":"BIOLOGICAL","name":"VIR-7831 (sotrovimab)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"VIR-7831 (Sotrovimab)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.","primaryOutcome":{"measure":"Number of Participants Who Had Progression of COVID-19 Through Day 29","timeFrame":"Through Day 29","effectByArm":[{"arm":"Sotrovimab (500 mg IV)","deltaMin":6,"sd":null},{"arm":"Placebo","deltaMin":30,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":91,"countries":["United States","Austria","Brazil","Canada","Peru","Spain","United Kingdom"]},"refs":{"pmids":["35977462","35285853","34706189","38074312","37702920","36703019","35713300","34473343"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":523},"commonTop":["Headache","Nausea","Diarrhea","Hypertension","Dyspnea"]}}